The CSIR, with support from WIPO, has just released its patent landscaping report on neglected human diseases.
The report’s conclusion raises an initial assumption that contrary to popular belief pharmaceutical companies are investing in R&D for neglected diseases. However, from a preliminary review, there are a number of questions concering the methodology used to assess the landscape for such a large number of patents, which naturally leads to the issue of patent quality.
The report provides a lot of raw data which will, Im sure, be analysed for some time by us and various interested parties.